Journavx (suzetrigine) / Vertex - LARVOL DELTA

Suzetrigine Versus Standard Analgesia After Skin Cancer Surgery (clinicaltrials.gov) - P4 | N=230 | Not yet recruiting | Sponsor: University of Minnesota

New P4 trial • Genetic Disorders • Head and Neck Cancer • Oncology • Pain • Skin Cancer

Suzetrigine Post DIEP (clinicaltrials.gov) - P3 | N=198 | Not yet recruiting | Sponsor: Vanderbilt University Medical Center

New P3 trial • Pain

Suzetrigine Added to Multimodal Analgesia for Women Undergoing Minimally Invasive Hysterectomy (clinicaltrials.gov) - P4 | N=123 | Not yet recruiting | Sponsor: Duke University

New P4 trial • Gynecology • Pain

Suzetrigine (Journavx) for Pain Management After Spine Surgery (clinicaltrials.gov) - P4 | N=110 | Not yet recruiting | Sponsor: Ohio State University

New P4 trial • Orthopedics • Pain

Suzetrigine Is Not Expected to Have Clinically Relevant DDIs with Apixaban and Rivaroxaban Based on PBPK Modeling. (PubMed, J Clin Pharmacol) - "The predicted small reductions in apixaban and rivaroxaban exposures (AUCinf <10%) are not expected to be clinically relevant since a 20% no-effect boundary is typically used to determine the clinical impact of a DDI. The PBPK model predictions are consistent with the apixaban and rivaroxaban labels, which do not warn against co-administration with weak or moderate CYP3A inducers, such as suzetrigine."

Journal • Pain

Suzetrigine: A Newly FDA-Approved Non-Opioid Treatment Option for Management of Moderate to Severe Acute Pain. (PubMed, Innov Clin Neurosci) - "The recent United States Food and Drug Administration approval of suzetrigine introduces a novel class of analgesics; however, its clinical impact has yet to be defined."

FDA event • Journal • Review • Aesthetic Medicine • Constipation • Dermatology • Gastroenterology • Gastrointestinal Disorder • Pain • Pruritus

Opioid-sparing Analgesia with Perioperative Suzetrigine in Head and Neck Free Flap Surgery (AAO-HNSF 2026) - "Opioid doses were converted to morphine milligram equivalents (MME). Adjunctive suzetrigine was associated with lower opioid use, greater perioperative reduction in daily opioid consumption, and maintained pain control, with fewer opioid refills and pain-related communications. These findings support suzetrigine as a component of multimodal opioid-sparing analgesia in head and neck reconstruction."

Surgery

Suzetrigine for Postoperative Pain in Head and Neck Free Flap or Transoral Robotic Surgery. (PubMed, JAMA Otolaryngol Head Neck Surg) - "Total inpatient morphine milligram equivalents (MMEs) consumed and MME consumption per hospital day. In this cohort study, adjunctive suzetrigine use was associated with lower postoperative opioid requirements after head and neck free flap reconstruction and transoral robotic surgery. Given the retrospective, nonrandomized design, these findings should be interpreted as associations warranting prospective confirmation."

Journal • Addiction (Opioid and Alcohol) • Hepatology • Liver Failure • Otorhinolaryngology • Pain • NAV1

Suzetrigine in Head and Neck Surgery: A New Frontier in Opioid Stewardship. (PubMed, JAMA Otolaryngol Head Neck Surg) - No abstract available

Journal • Otorhinolaryngology

Deeper delving Nav1.8 inhibitor Suzetrigine in chronic pain. (PubMed, Acta Pharmacol Sin) - "Recent studies using Suzetrigine on neuronal excitability of human dorsal root ganglion partially support its effects on chronic pain, while some case reports demonstrated discouraging effects, implying the insufficiency of solid evidence to support its effects in chronic pain and a long gap from clinical application, which may be warranted by further well-designed clinical trials. This Perspective highlighted some concerns for future studies about Suzetrigine in chronic pain."

Journal • Pain • NAV1

STOP: Suzetrigine in Tonsillectomy for Opioid-sparing Pain Management (clinicaltrials.gov) - P4 | N=58 | Not yet recruiting | Sponsor: Stanford University

New P4 trial • Pain

Suzetrigine for Non-Mastectomy Breast Surgery (clinicaltrials.gov) - P4 | N=120 | Enrolling by invitation | Sponsor: University of California, San Diego | Trial completion date: Dec 2027 ➔ Jun 2027 | Trial primary completion date: Dec 2027 ➔ Jun 2027

Trial completion date • Trial primary completion date • Pain

Suzetrigine for Opioid-Sparing Postoperative Analgesia Following Transvaginal Pelvic Reconstructive Surgery (clinicaltrials.gov) - P4 | N=120 | Not yet recruiting | Sponsor: University of California, Los Angeles | Initiation date: Jul 2026 ➔ Nov 2026

Trial initiation date • Pain • Urinary Incontinence • Urology

Post-op Analgesia of Nail Unit Procedures (clinicaltrials.gov) - P4 | N=45 | Not yet recruiting | Sponsor: University of Miami

New P4 trial

A Phase 3 Multiple-dose Efficacy and Safety Trial of a Novel Fixed Dose Combination of Acetaminophen and Naproxen Sodium in a Post-surgical Bunionectomy Pain Model (PAINWeek 2026) - "Postsurgical bunionectomy pain is a well-established and reliable pain model that has been used to assess moderate- and high-potency analgesics and support regulatory agency review and approval of many prescription analgesics, including, suzetrigine and hydrocodone bitartrate/acetaminophen... Among 143 randomized participants, mean baseline pain intensity score was 7.6 on PI-NRS with 86 (60.1%) reporting moderate and 57 (39.9%) severe pain. FDC Acet650/NPX220 participants reported greater reductions in pain intensity compared with placebo throughout the trial (SPID 0-12, 15.2 and 2.6, respectively; SPID 0-24 [primary endpoint], 48.4 and 14.2, respectively; SPID 0-48, 151.5 and 68.3, respectively; each p< 0.001). FDC Acet650/NPX220 participants reported significantly greater PID compared with placebo from 3-48 hours (p< 0.05 across timepoints)."

Clinical • P3 data • CNS Disorders • Pain

Opioid-Sparing Effect of Suzetrigine in Total Knee Arthroplasty and Knee Arthroplasty Revision (PAINWeek 2026) - "Generalizability of results is limited by surgeries studied (ie, abdominoplasty and bunionectomy), an inconsistent efficacy benefit compared with hydrocodone-acetaminophen, and a uncertain impact on opioid use...Outcomes evaluated included postoperative opioid prescribing at discharge and prior to the 2-week follow-up appointment (quantified by Morphine Equivalent Daily Dose [MEDD] and total Morphine Milligram Equivalents [MME]), pain control and functional recovery (assessed via pre- and postoperative knee Range of Motion [ROM], Knee injury and Osteoarthritis Outcome Score for Joint Replacement [KOOS JR], and Patient-Reported Outcomes Measurement Information System [PROMIS] scores)...The perioperative standard of care was consistent across the evaluation period; this included an intraoperative “joint cocktail” (bupivacaine, ketorolac, epinephrine +/- clonidine) and a postoperative multimodal regimen of scheduled acetaminophen and NSAID unless contraindicated, in..."

Addiction (Opioid and Alcohol) • CNS Disorders • NAV1

Chronic Pain as a Precision-Weighting Disorder: A Predictive-Processing Framework and Open-Shape-Stabilize Hypothesis (PAINWeek 2026) - "Open: subanesthetic ketamine transiently destabilizes maladaptive precision weighting via cortical interneuron disinhibition and a thalamic burst-to-tonic shift; the framework is pharmacologically agnostic, with serotonergic psychedelics (5-HT2A-mediated hierarchy flattening) as a mechanistically orthogonal opener generating overlapping biomarker predictions. Shape: top-down rTMS and individual-alpha-matched tACS combined with bottom-up short-course NaV1.8 blockade (suzetrigine); sustained low-magnitude nociceptive input during the plasticity window is predicted to bias the system toward a body-safe inference, yielding a dose-response prediction in which the duration of afferent reduction within the window, not merely its presence, should matter... The framework yields an integrated account comprising three central claims and a structured intervention hypothesis. First, the convergence claim: if the precision-assignment mechanism is broadly dysregulated, chronic pain,..."

CNS Disorders • Depression • Mood Disorders • Pain • NAV1

Real-World Suzetrigine Administration and Prescribing for Postoperative Pain Among Older Adults in the U.S. Health Systems (PAINWeek 2026) - "Among 1,804 patients meeting the selection criteria, all were indexed in the hospital setting receiving SUZ as inpatient administration or a written discharge prescription. Mean age was 74.4 years, 60.1% were female, and common comorbidities were dyslipidemia, hypertension, and osteoarthritis. Common surgery types included orthopedics and general surgeries; the majority were outpatient (85.5%)."

Clinical • Real-world • Real-world evidence • CNS Disorders • Pain • NAV1

12-Month Post-Launch Suzetrigine Prescription Fill Patterns in Real-World Settings (PAINWeek 2026) - "A total of 6,324 patients with suzetrigine prescription fills met the study selection criteria. Mean age was 55.9 years and 62.6% were female. The median days’ supply of the initial suzetrigine prescription was 15 days."

Clinical • Real-world • Real-world evidence • Back Pain • CNS Disorders • Lumbar Back Pain • Musculoskeletal Pain

Evaluating the Impact of Suzetrigine on Opioid Prescribing Patterns in Total Knee Arthroplasty (PAINWeek 2026) - "Acknowledgements (financial assistance and/or AI assistance) : Funding for this study was provided by Vertex Pharmaceuticals. This study included 106 patients in the SUZ cohort and 1,487 in the control cohort. Compared with controls, a greater proportion of patients in the SUZ cohort were discharged without an opioid prescription in both outpatient (62.0% vs. 21.1%) and inpatient (51.8% vs."

Addiction (Opioid and Alcohol) • CNS Disorders

Suzetrigine Prescribing Patterns in the 12-Months Following Approval: An Analysis of the Walgreens Retail Pharmacy Database (PAINWeek 2026) - "The initial analysis included 77,134 patients with at least one suzetrigine prescription order. The mean age was 59.3 years (range: 17 to 105 years), 40.6% of all patients were aged ≥65, and 63.4% were female. The median index suzetrigine prescription order was for 14 days; more than three-quarters of initial prescription orders (76.0%) were for ≤15 days."

CNS Disorders

Pain management after Mohs: A randomized clinical trial of Suzetrigine versus hydrocodone/acetaminophen. (PubMed, J Eur Acad Dermatol Venereol) - No abstract available

Clinical • Journal • Genetic Disorders • Oncology • Pain • Skin Cancer

Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants (clinicaltrials.gov) - P1 | N=13 | Completed | Sponsor: Vertex Pharmaceuticals Incorporated | Recruiting ➔ Completed | Trial completion date: Feb 2027 ➔ Aug 2026 | Trial primary completion date: Feb 2027 ➔ Aug 2026

Trial completion • Trial completion date • Trial primary completion date • Pain

Myotonic Muscle Activity Drives a Persistent Pain State Responsive to NaV1.8-directed Analgesics. (PubMed, J Clin Invest) - "Transient myotonia increased total sodium current density in sensory neurons, with a shift toward a greater tetrodotoxin-resistant current fraction. Pharmacological inhibition with the NaV1.8-directed analgesic Suzetrigine markedly attenuated pain-like behaviors in both models of myotonia. Together, these findings establish a link between myotonia and persistent alterations in nociceptive processing and identify NaV1.8-directed analgesia as a promising therapeutic strategy for myotonia-associated pain."

Journal • CNS Disorders • Immunology • Inflammation • Pain • NAV1

Pharmacological Management of Diabetic Neuropathy: Current Evidence, Clinical Positioning, and Emerging Therapeutic Targets. (PubMed, Curr Neuropharmacol) - "Managing diabetic neuropathy necessitates personalized treatment that equilibrates analgesia with tolerability. Current medications primarily alleviate symptoms; however, ongoing investigations into antioxidant and neuroprotective agents present the potential for therapies that may decelerate or reverse nerve damage."

Journal • Addiction (Opioid and Alcohol) • Anesthesia • Diabetes • Diabetic Neuropathy • Inflammation • Metabolic Disorders • Neuralgia • Pain